TABLE OF CONTENTSn n I. Overview of AML: Francis Giles, MD Andersonn II. Molecular Foundations of AML Pathogenesis and Pathophysiologyn A. Transcriptional Control of Myeloid Differentiation and Transformation: Alan Friedman, Johns Hopkins n B. Myelodysplasia-Related AML: Ghulam Mufti, King's College, London, Englandn C. Treatment-Related AML: Michelle LeBeau, University of Chicagon D. DNA Damage and Repair: David Steensma and Scott Kaufmann Mayo Clinicn E. Apoptosis: Ruben Mesa and Scott Kaufmann, Mayo Clinicn F. Drug Resistance Transporters: Douglas Ross, University of Marylandn III. Translating Biology into Clinical Application n A. Impact of Cytogenetics on Clinical Outcome: David Grimwade, Guy's Hospital, London, England n B. APL: A Classic Tale of Bench to Bedside: Martin Tallman, Northwestern n C. Molecular Therapeutics of AML: Selected Targeted Approaches n Overview: Edward Sausville, University of Marylandn FLT3: Mark Levis, Johns Hopkinsn Farnesyltransferase: Jeffrey Lancet, Moffitt (University of South Florida)n Modulating Gene Expression as a Therapeutic Approach: Tamer Fandy, n Hetty Carraway, Steven Gore, Johns Hopkins n Growth Factor-Based Differentiation: William Matsui, Johns Hopkinsn D. Stem Cell Transplantation: Richard Jones, Johns Hopkinsn E. Vaccine Development: Ivan Borrello, Johns Hopkinsn IV. Special Challengesn A. Pediatric AML: Robert Arceci, Johns Hopkins -- pending n B. AML in the Elderly: Richard Stone, Dana Farber n C. Myeloproliferative Disorders: Jason Gottlib, Stanfordn D. New Clinical Trials Designs: Elihu Estey, MD Anderson
This is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. There is an emphasis throughout on the bidirectional flow of knowledge between the clinical and laboratory arenas.
Novel therapeutic concepts based on AML cell biology
Critical factors in leukemia cell survival and drug resistance, and their potential exploitation as therapeutic targets